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Background    There have been no guidelines for the management of adult patients with diffuse mid-
line glioma (DMG), H3K27M-mutant in Korea since the 2016 revised WHO classification newly defined 
this disease entity. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic 
society, had begun preparing guidelines for DMG since 2019.
Methods    The Working Group was composed of 27 multidisciplinary medical experts in Korea. 
References were identified through searches of PubMed, MEDLINE, EMBASE, and Cochrane CEN-
TRAL using specific and sensitive keywords as well as combinations of keywords. As ‘diffuse midline 
glioma’ was recently defined, and there was no international guideline, trials and guidelines of ‘diffuse 
intrinsic pontine glioma’ or ‘brain stem glioma’ were thoroughly reviewed first.
Results    The core contents are as follows. The DMG can be diagnosed when all of the follow-
ing three criteria are satisfied: the presence of the H3K27M mutation, midline location, and infiltrating 
feature. Without identification of H3K27M mutation by diagnostic biopsy, DMG cannot be diagnosed. 
For the primary treatment, maximal safe resection should be considered for tumors when feasible. Ra-
diotherapy is the primary option for tumors in case the total resection is not possible. A total dose of 
54 Gy to 60 Gy with conventional fractionation prescribed at 1-2 cm plus gross tumor volume is rec-
ommended. Although no chemotherapy has proven to be effective in DMG, concurrent chemoradio-
therapy (± maintenance chemotherapy) with temozolomide following WHO grade IV glioblastoma’s 
protocol is recommended.
Conclusion    The detection of H3K27M mutation is the most important diagnostic criteria for DMG. 
Combination of surgery (if amenable to surgery), radiotherapy, and chemotherapy based on compre-
hensive multidisciplinary discussion can be considered as the treatment options for DMG.
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INTRODUCTION
‘Diffuse midline glioma (DMG), H3K27M-mutant’ is a new-
ly established disease entity according to the 2016 revised ver-
sion of the World Health Organization (WHO) classification 
of brain tumors [1]. H3K27M-mutant DMGs are high-grade 
gliomas (WHO grade IV) associated with local infiltration and 
a poor prognosis of an average survival time of less than one 
year [2]. The pons is the most common location of H3K27M-
mutant DMG, however, they can also occur in the thalamus, 
spinal cord, and other midline locations in patients of all DMGs 
[3]. Importantly, H3K27M-mutant DMG is a pathologic di-
agnosis and is not synonymous with the clinical and radiologic 
entity of diffuse intrinsic pontine glioma (DIPG). DMG is a 
part of disease that was previously classified as ‘DIPG’ or ‘brain 
stem glioma’. Approximately 80% of biopsied DIPGs harbor 
mutations at position K27 in one of several histone-encoding 
genes [4-6].
Despite the dismal prognosis of DMG, there are few random-
ized controlled clinical trials to establish the evidence-based 
standard treatment protocol. In general, surgery, radiotherapy, 
and chemotherapy can be considered as treatment options for 
DMG. If it is feasible, maximal safe resection can be considered 
as an initial treatment of choice. However, no superior treat-
ment modalities including radiotherapy, chemotherapy, and/
or surgery, have been recommended alone or in combination 
to others. There are no unified (inter)national guidelines of ra-
dio- and chemotherapy for DMG, which resulted in a hetero-
geneous application of treatments. 
A practical guideline for the management of patients with 
central nervous system (CNS) tumors in Korea has been limit-
ed. Therefore, the Korean Society for Neuro-Oncology (KSNO), 
a multidisciplinary academic society for CNS tumors, began 
to prepare guidelines for various types of brain tumors from 
February 2018. In 2019, a new Guideline Working Group chap-
ter began to develop the practical guidelines for the manage-
ment of DMG in Korea. The main purpose of KSNO guide-
lines for DMG is to 1) provide an opportunity to share relevant 
medical knowledge and experiences among experts through 
the development of treatment guidelines, 2) provide practical 
standard treatment information to medical staffs, 3) help de-
termining the optimal treatment strategies for DMG through 
multidisciplinary approaches, and 4) prolong patient’s life, im-
prove quality of life, and ultimately contribute to the improve-
ment of national health.
KSNO GUIDELINE WORKING GROUP
A new chapter of Working Group was appointed by the KSNO 
in 2019 to develop a clinical guideline for management of pa-
tients with brain tumor. These guidelines should be optimized 
considering the unique medical circumstance in Korea. The 
KSNO Guideline Working Group was composed of 27 medi-
cal experts in Korea, including 15 neurosurgeons, 6 radiation 
oncologists, 1 medical oncologist, 2 neuroradiologists, 2 pa-
thologists, and 1 neurologist.
References were identified by searching PubMed, MEDLINE, 
EMBASE, and Cochrane CENTRAL databases using specific 
and sensitive keywords as well as combinations of keywords. 
After ‘diffuse midline glioma, H3K27M-mutant’ was proposed 
as a new diagnostic entity in 2016, all retrospective and pro-
spective clinical studies of this disease were reviewed. As there 
was no international guideline for management of DMG yet, 
the guidelines for the treatment of ‘DIPG’ or ‘brain stem glioma’ 
were also reviewed to develop this new guideline. If available, 
existing guidelines from national multidisciplinary neuro-on-
cological societies such as the National Comprehensive Cancer 
Network (NCCN) and European Association of Neuro-Oncol-
ogy (EANO) were also collected. The language was limited to 
English and Korean. The publication year was not limited, but 
the papers published after 2016 were weighted more because 
DMG is a newly established disease entity since 2016. The se-
lection of search terms and selection of suitable papers were 
conducted by reflecting the opinions of the members in charge. 
After reviewing the papers, a total of 51 papers were selected 
as references for this guideline.
Scientific evidence was evaluated and graded according to 
the following categories: high level evidence (obtained from 
multiple populations and derived from randomized clinical 
trials or meta-analysis or systemic review), and low level evi-
dence (obtained from limited population and derived from 
non-randomized studies, including observational studies, co-
hort studies, and case-control studies).
To establish the recommendation levels, the following cri-
teria were used. Level I (strong recommendation) required a 
high level evidence and uniform agreement among panels. Level 
II (weak recommendation) required a high level evidence but 
not uniform agreement among panels or low level evidence 
but uniform agreement among panels. Level III (no consen-
sus; individual decision) required a low level evidence but not 
uniform agreement among panels. Level IV (not recommend-
ed) required contents being not beneficial or harmful.
DIAGNOSIS OF DIFFUSE MIDLINE 
GLIOMA 
DMG is a rare type of glial tumor that occurs in the CNS. 
Previously, it referred to as ‘DIPG.’ More recently, it was known 
that some DIPGs with a specific mutation (H3K27M muta-
tion) show characteristically dismal prognosis. Therefore, the 
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when physicians diagnose this disease entity radiologically. 
In summary, DMG can be diagnosed when all of the follow-
ing three criteria are satisfied: 1) the presence of the H3K27M 
(H3F3A or HIST1H3B/C) mutation, 2) midline location (thal-
amus, brain stem, spinal cord, etc.), and 3) infiltrating (diffuse) 
feature (Level I). Since the confirmation of H3K27M mutation 
is the most important diagnostic criteria for DMG rather than 
clinical and imaging features, tumor biopsy should be consid-
ered first (Level I) and immunostaining for the histone H3K27M 
mutation should be performed to detect the H3K27M mutation 
(Level I) [15]. Instead, detection of EGFR hotspot mutation or 
EZHIP overexpression can be used to diagnosis DMGs [16]. 
If histopathological feature of diffusely infiltrative growth in 
glioma at midline location and H3K27M mutation are detect-
ed, physicians can diagnose DMG (Level I). Even if H3K27M 
mutation is detected, physicians cannot diagnose DMG if the 
tumor is not located at the midline location (Level II). If the 
diagnostic biopsy is not possible or H3K27M mutation is not 
identified, the tumor cannot be diagnosed as DMG even if both 
location (midline) and infiltrating feature are satisfied. In this 
case, it is advisable to follow the treatment guidelines of other 
types of glioma in WHO classification (Level I) (Fig. 1, Table 1).
2016 revised WHO classification redefined this type of tumors 
as ‘diffuse midline glioma, H3K27M-mutant’, a new diagnos-
tic entity based on its unique genetic signature [1]. Charac-
teristically, 1) it is located in the midline of the brain (brain 
stem, spinal cord, cerebellum, thalamus, etc.), 2) shows a dif-
fuse growth pattern, and 3) shows K27M mutation in H3F3A 
or HIST1H3B/C (H3K27M mutation) [7-9]. Because surgical 
resection is often difficult due to the delicate location of the 
tumor [10,11], proper imaging and biopsy are required for ac-
curate diagnosis of DMG [12,13]. However, in some tumors, 
the location is often not suitable to perform a biopsy [10,11]. 
According to the previous European survey for health care pro-
fessionals treating DIPG patients, only 13.5% of the respondents 
said to do biopsy all of their patients, while 41.9% of the respon-
dents said to do biopsy their patients infrequently [14]. Char-
acteristic radiologic findings shown only in DMG have not yet 
been clearly defined, and studies involving adult patients are 
further lacking. In general, when diagnosing by imaging find-
ings without confirming the presence of H3K27M mutation, 
the presence of ‘extensive invasion’ in the midline structures of 
the CNS is an important finding. However, as these radiolog-
ic features are not shown in all cases, and histologic confirma-
tion is more critical, sufficient discussion should be preceded 
① Presence of the H3K27M mutation
② Midline location
③ Infiltrating (diffuse) feature*
*Histopathological feature of diffusely infiltrative growth
④ H3K27M mutation: negative or not confirmed
Treatment guidelines
“Diffuse midline glioma”
• Maximal safe resection, if possible
• Radiotherapy (concurrent temozolomide) followed by maintenance temozolomide
Other types of gliomas
Fig. 1. Diagnosis algorithm for diffuse midline glioma (DMG). To diagnose DMGs, detection of H3K27M mutation, the location of tumor 
(midline location), and infiltrating feature are essential (①+②+③). In other words, physicians are not recommended to diagnose DMG if the 
tumor is not located at the midline location (②), even if H3K27M mutation is detected (①). Also, if the diagnostic biopsy is not possible or 
H3K27M mutation is not identified (④), the tumor cannot be diagnosed as DMG even if both location (midline) (②) and infiltrating feature (③) 
are satisfied. 
Table 1. Guideline for diagnosis of diffuse midline glioma 
Question 1. How should diffuse midline glioma be diagnosed?
Recommendation 
level
1-1. Diffuse midline glioma can be diagnosed when the following three criteria are satisfied: Level I
① Presence of the H3K27M (H3F3A or HIST1H3B/C) mutation
② Midline location (thalamus, brain stem, spinal cord, etc.)
③ Infiltrating (diffuse) feature (histopathologically) 
1-2. To detect the H3K27M mutation, immunostaining for the histone H3K27M mutation should be performed. Level I
1-3.  Even if H3K27M mutation is detected (①), physicians cannot diagnose diffuse midline glioma if the tumor is not 
located at the midline location (②).
Level II
1-4.  If the diagnostic biopsy is not possible or H3K27M mutation is not identified, the tumor cannot be diagnosed as  
diffuse midline glioma even if both ② and ③ are satisfied. In this case, it is advisable to follow the treatment  
guidelines of other types of glioma in WHO classification.
Level I
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PRINCIPLES OF MANAGEMENT OF 
DIFFUSE MIDLINE GLIOMAS  
Decision for primary treatment 
Customarily, managements of DMG have followed the stan-
dards of care for gliomas of the same WHO grade [17,18]. Com-
binations of surgery, radiotherapy, and chemotherapy can be 
considered as the treatment options for DMG [14,15,19]. For 
tumors that can be surgically resected safely, maximal safe re-
section should be considered first (Level II). The goal of sur-
gery is to obtain tissue for genetic diagnosis and to reduce the 
tumor burden without harming neurological status of the pa-
tient [15,18-20]. However, the brainstem, thalamus, and spinal 
cord are neurologically critical structures and surgical proce-
dures in these areas can cause serious irreversible deficits. Thus, 
management strategies including the scope and purpose of 
the surgery must be carefully determined through multidisci-
plinary discussion (Level II). Even if maximal safe resection is 
not feasible, biopsy of the tumor should be essentially consid-
ered to confirm the presence of H3K27M mutation for the di-
agnosis of DMG (Level II). 
In addition to the surgical resection, radiotherapy and che-
motherapy can also be added for the management of DMG 
[10,14,15,17,19]. Radiotherapy is the primary treatment op-
tion when the complete surgical resection is not feasible which 
is in the majority of cases (Level II). Concurrent chemotherapy 
using temozolomide can be considered when performing ra-
diotherapy (Level II). Sequential chemotherapy after radiother-
apy can also be performed in some cases. However, there has 
been no chemotherapy regimen which demonstrated mean-
ingful benefit in DMG [21-23]. There is also a lack of reports 
that concurrent chemotherapy is superior to radiotherapy fol-
lowed by chemotherapy, radiotherapy alone, or chemotherapy 
alone. Given these limitations, each plan should be tailored 
to each patient. A multidisciplinary discussion among ex-
perts including neuro-oncologists, neuroradiologists, radia-
tion oncologists, and neurosurgeons, is important to deter-
mine the best treatment plan. At any time during the course 
of treatment, it is necessary to actively apply symptom-con-
trolling drugs or procedures such as steroids or ventriculo-
peritoneal shunt when necessary (Level I) (Table 2). 
Radiotherapy
To determine the dose scheme of radiotherapy, it would be 
reasonable to follow the radiotherapy policy of DIPG, as the 
relevant papers for DMG are still lacking. Radiotherapy has 
been regarded as an important treatment option for brainstem 
glioma. In current situation, similar doses and fields can be rec-
ommended when performing radiotherapy in DMG. A total 
dose of 54 Gy to 60 Gy with conventional fractionation (1.8–
2.0 Gy daily given five days per week) is recommended (Level II) 
[24]. Total dose of radiation should be determined by radia-
tion oncologists. The dose-constraint of the brainstem should 
always be kept (Level II). Dose escalation is not recommended 
(Level II). The radiotherapy field can be defined as 1–2 cm plus 
gross tumor volume (GTV) (Level II) [25]. GTV includes not 
only contrast-enhancing lesions but also hyperintense lesions 
seen on T2-weighted, FLAIR images (Level II). For radiother-
apy techniques, three-dimensional conformal radiation therapy 
using X-rays, intensity-modulated radiation therapy, and pro-
ton therapy [26] can be considered for radiotherapy techniques 
(Level II).
Despite multiple trials of dose escalation, hyperfractionated 
radiotherapy [27-35], hypofractionated radiotherapy [36-40], 
and radiosensitization, none of these modulations have been 
proven more effective than the conventional radiotherapy. Pa-
tients with severe symptoms may require urgent initiation of 
radiotherapy. Due to the poor prognosis in patients with DIPG, 
hypofractionated radiation therapy has been evaluated to mini-
mize the time spent in treatment. In a randomized trial of 71 
children with newly diagnosed DIPG, a regimen of thirteen 3.0 
Gy fractions was well tolerated, and median overall survival ap-
proached that of radiation therapy given over six weeks (7.8 
versus 9.5 months) [36,41]. Based on this result, depending on 
Table 2. Guideline for primary treatment decision of patients with diffuse midline glioma
Question 2. What is the primary treatment for diffuse midline glioma?
Recommendation 
level
2-1.  Surgery, radiotherapy, and chemotherapy can be considered as the treatment options for diffuse midline glioma. The  
scope of surgery and treatment policy for each patient should be determined through multidisciplinary discussion. 
Level II
2-2. For tumors that can be surgically resected safely, maximal safe resection should be considered first. Level II
2-3.  Even if maximal safe resection is impossible considering the tumor location, possibility of tumor biopsy to confirm 
the presence of H3K27M mutation should be checked to diagnose diffuse midline glioma.
Level II
2-4.  Radiotherapy is the primary treatment option for tumors in which total surgical resection is not possible, or only 
partial resection is performed.
Level II
2-5. Concurrent chemotherapy should be considered when performing radiotherapy. Level II
2-6. When a tumor causes neurological or systemic symptoms, it is necessary to actively apply symptom-controlling drugs. Level I 
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Chemotherapy
No chemotherapy has been proven to be effective in DMG 
or DIPG. Numerous treatment protocols, including single 
chemotherapy agents, multi-drug combination regimens, and 
high-dose therapy with stem cell rescue, have been tested in 
both adults and children without clear evidence of benefit [14, 
48-55]. Although temozolomide has become part of standard 
therapy for most adult patients with high-grade gliomas, test-
ing in combination with radiotherapy for newly diagnosed 
DIPG has demonstrated no improvement in activity compared 
with radiation alone and is associated with increased risk for 
side effects and toxicity [38,52,55]. Besides, the incidence of 
O6-methylguanine-DNA methyltransferase (MGMT) meth-
ylation itself was reported to be low in DMG [9]. Clinical tri-
als using other drugs, such as gefitinib, ONC201, and panobi-
nostat, failed to show any clear benefits [56-60].
Nevertheless, temozolomide can be considered first as a che-
motherapy regimen in DMG during- and post-radiotherapy 
(Level II) in the absence of other suitable chemotherapy regi-
the patient’s condition and tumor location, the corresponding 
dose with hypo-fractionation can also be prescribed instead of 
54–60 Gy with conventional fractionation in DMG (Level III). 
Fractionated re-irradiation may be considered at the time of 
progression to temporarily extend palliation, although increased 
toxicities may result from this approach [42,43]. In a small pro-
spective dose-escalation study of DMG, the lowest dose level 
(24 Gy in 12 fractions) was well tolerated and achieved imag-
ing, clinical, and/or quality-of-life improvement in most pa-
tients; in all 12 patients, progression-free and overall survival 
from the start of re-irradiation were 4.5 and 5.8 months, re-
spectively [44]. Also, re-irradiation may be considered to con-
trol symptoms and improve the survival outcomes in well-se-
lected patients with persistent disease progression [42,45-47]. 
For the re-irradiation dose, 20–40 Gy with conventional frac-
tionation can be recommended based on recent studies (Level 
III). Depending on the patient’s condition, corresponding dose 
with hypo-fractionation radiotherapy (≤3 Gy per fraction) can 
also be prescribed (Table 3).
Table 3. Guideline for radiotherapy of patients with diffuse midline glioma
Question 3. How should radiotherapy be performed in diffuse midline glioma?
Recommendation 
level
3-1.  A total dose of 54 Gy to 60 Gy with conventional fractionation (1.8–2.0 Gy daily given five days per week) is  
recommended;
Level II
i) Dose escalation is not recommended. Level II
ii)  Total dose of radiation should be determined by radiation oncologists. The dose-constraint of the brain stem should 
always be kept.
Level II
3-2.  Depending on the patient’s condition and tumor location, the corresponding dose with hypo-fractionation can also 
be prescribed instead of 54–60 Gy with conventional fractionation.
Level III
3-3.  The radiotherapy field can be defined as 1–2 cm plus gross tumor volume (GTV). GTV includes not only  
contrast-enhancing lesions but also hyperintense lesions seen on T2-weighted, FLAIR images.
Level II
3-4.  Three-dimensional conformal radiation therapy using X-rays, intensity-modulated radiation therapy, and proton 
therapy can be considered for radiotherapy techniques.
Level II
3-5.  Re-irradiation may be considered to control symptoms and improve the survival outcomes in some patients with  
persistent disease progression. For the re-irradiation dose, 20–40 Gy with conventional fractionation can be  
prescribed.
Level III
Table 4. Guideline for chemotherapy of patients with diffuse midline glioma
Question 4. How should chemotherapy be performed in diffuse midline glioma?
Recommendation 
level
4-1.  Concurrent chemoradiotherapy (± maintenance chemotherapy) can be considered a primary treatment or adjuvant 
treatment after surgery.
Level II
4-2.  As a chemotherapy regimen, temozolomide can be used during- and post-radiotherapy following WHO grade IV 
glioblastoma’s Stupp regimen protocol.
Level II
4-3.  When concurrent chemoradiotherapy is unsuitable considering the patient’s condition, radiotherapy alone is  
recommended.
Level II
4-4. If the disease progresses after radiotherapy, maintenance chemotherapy with temozolomide can be applied. Level III 
4-5.  The single agent or combination therapy of chemotherapeutic agents other than temozolomide can be tried only after 
sufficient multidisciplinary discussion.
Level III 
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men. The reason is that temozolomide has been proven to be 
an effective and safe drug for the same WHO grade (grade IV) 
of other brain tumors. In addition, temozolomide acts as a ra-
dio-sensitizer when administered together with radiotherapy, 
thereby enhancing the therapeutic effects of radiation. There-
fore, concurrent chemoradiotherapy (± maintenance chemo-
therapy) can be considered a primary treatment or adjuvant 
treatment after surgery in DMG (Level II). However, since con-
current chemoradiotherapy may increase treatment-related 
toxicity, careful decision case by case is needed considering the 
patient’s condition. If the patient is in old age or in poor con-
dition, temozolomide may be prescribed sequentially after ra-
diotherapy or radiotherapy alone is recommended (Level II). 
If the disease progresses after radiotherapy, maintenance che-
motherapy using temozolomide can be applied (Level III). The 
single agent or combination therapy of chemotherapeutic agents 
other than temozolomide can be tried only after full multidis-
ciplinary discussion (Level III). Clinical trials are currently being 
attempted to prove the effectiveness of other chemotherapeu-
tic agents in DMG, and according to the results, recommenda-
tions for chemotherapy may change shortly (Table 4).
CONCLUSION
Until now, there has been no practical guideline for the man-
agement of adult patients with DMG in Korea. Thus, the KSNO 
developed this guideline applicable to the current medical cir-
cumstances in Korea. “The KSNO Guideline for Adult Diffuse 
Midline Glioma: Version 2021.01” is the first guideline for 
H3K27M-mutant diffuse midline glioma in Korea (Fig. 2), 
prepared by the KSNO Guideline Working Group. 
In summary, it is recommended to confirm the presence of 
H3K27M mutation after the maximal safe resection or biop-
sy to diagnose the DMG. Radiotherapy is recommended as a 
primary (or adjuvant) treatment option for tumors incapable 
of complete resection and concurrent chemotherapy with te-
mozolomide can be considered. However, considering that ev-
idence is still lacking, and treatment-related toxicity may be 
increased in some patients after concurrent radio-chemother-
apy, treatment policy for each patient should be determined 
through sufficient multidisciplinary discussion.
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